21 CFR 330.11 - NDA deviations from applicable monograph.
A new drug application requesting approval of an OTC drug deviating in any respect from a monograph that has become final shall be in the form required by § 314.50 of this chapter, but shall include a statement that the product meets all conditions of the applicable monograph except for the deviation for which approval is requested and may omit all information except that pertinent to the deviation.
[39 FR 11741, Mar. 29, 1974, as amended at 55 FR 11581, Mar. 29, 1990]
Title 21 published on 2014-04-01.
No entries appear in the Federal Register after this date, for 21 CFR Part 330.